Javascript must be enabled to continue!
Incorporating Prior Genomic Dose-Response Data to Support the Benchmark Dose Estimation of Toxicogenomics
View through CrossRef
AbstractChemical risk assessment is an important tool to evaluate the toxicity of chemicals in the environment, and high throughput toxicogenomics plays an increasingly important role in risk assessment. In toxicogenomics, dose-response analysis for each gene is a data-limited situation, and thus parameter and benchmark dose (BMD) estimations typically have large uncertainty. To solve this problem, an informative prior by synthesizing toxicological information is integrated into the Bayesian benchmark dose modeling system (BBMD), a leading web-based toxicogenomics analysis application. We analyzed 276,126 toxicogenomics dose-response datasets and obtained plausible estimation of informative priors for seven commonly used continuous dose-response models. The effects of informative priors are investigated at the individual probe and pathway levels. Simulation studies based on six “true” models generated from typical genomic dose-response shapes show a significant decrease in uncertainty and an increase in accuracy of BMD estimates for most scenarios with informative priors than the counterpart with uninformative priors. The case study on the pathway analysis indicates that informative priors slightly improve the correlation between the pathway-based point of departure and apical point of departure. Overall, our study provides a practical strategy to incorporate existing toxicogenomic information as priors to improve the quality of chemical risk assessment.Graphic abstract
Title: Incorporating Prior Genomic Dose-Response Data to Support the Benchmark Dose Estimation of Toxicogenomics
Description:
AbstractChemical risk assessment is an important tool to evaluate the toxicity of chemicals in the environment, and high throughput toxicogenomics plays an increasingly important role in risk assessment.
In toxicogenomics, dose-response analysis for each gene is a data-limited situation, and thus parameter and benchmark dose (BMD) estimations typically have large uncertainty.
To solve this problem, an informative prior by synthesizing toxicological information is integrated into the Bayesian benchmark dose modeling system (BBMD), a leading web-based toxicogenomics analysis application.
We analyzed 276,126 toxicogenomics dose-response datasets and obtained plausible estimation of informative priors for seven commonly used continuous dose-response models.
The effects of informative priors are investigated at the individual probe and pathway levels.
Simulation studies based on six “true” models generated from typical genomic dose-response shapes show a significant decrease in uncertainty and an increase in accuracy of BMD estimates for most scenarios with informative priors than the counterpart with uninformative priors.
The case study on the pathway analysis indicates that informative priors slightly improve the correlation between the pathway-based point of departure and apical point of departure.
Overall, our study provides a practical strategy to incorporate existing toxicogenomic information as priors to improve the quality of chemical risk assessment.
Graphic abstract.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
10 Years of Toxicogenomics section in Frontiers in Genetics: Past discoveries and Future Perspectives
10 Years of Toxicogenomics section in Frontiers in Genetics: Past discoveries and Future Perspectives
The Frontiers Media family has over 200 journals, which are each headed by usually one Field Chief Editor, and several specialty sections, which are each headed by one or more Spec...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Toxicogenomics — Applications in Systems Toxicology
Toxicogenomics — Applications in Systems Toxicology
AbstractHuman exposure to toxic chemicals is almost unavoidable. The toxicity owing to human exposure to chemicals may result in adverse health effects such as illnesses and even d...

